共 281 条
[1]
Borgstrom F(2020)Fragility fractures in Europe: burden, management and opportunities Arch Osteoporos 15 59-17
[2]
Karlsson L(2019)Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women Aging Clin Exp Res 31 15-705
[3]
Ortsater G(2012)A new taxonomy for describing and defining adherence to medications Br J Clin Pharmacol 73 691-2165
[4]
Norton N(2019)Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) Osteoporos Int 30 2155-210
[5]
Halbout P(2010)Potential clinical and economic impact of nonadherence with osteoporosis medications Calcif Tissue Int 86 202-2637
[6]
Cooper C(2018)A systematic review of factors affecting medication adherence among patients with osteoporosis Osteoporos Int 29 2623-276
[7]
Kanis JA(2012)Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet Osteoporos Int 23 267-62
[8]
Cooper C(2012)Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate Int J Pharm 432 57-S773
[9]
Rizzoli R(2019)Upper gastrointestinal safety with the buffered solution of alendronate 70 mg: 6 years of post-marketing experience Osteoporos Int 30 S253-224
[10]
Reginster JY(2015)A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis Pharmacoeconomics 33 205-57